Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-28 in advanced solid tumors including pancreatic carcinoma
ACTRN12625001342404Phase 2Not yet recruiting
- Sponsor
- Second Life Therapeutics, Inc.
- Start
- Dec 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of SL-28 in pancreatic adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), small cell lung cancer (SCLC) and 13 more (3 arms), sponsored by Second Life Therapeutics, Inc. Primary endpoints: Safety and tolerability of SL-28 and Incidence of dose-limiting toxicities. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
SL-28
03
Conditions
pancreatic adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on ACTRN12625001342404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001342404.